The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect
Tóm tắt
Từ khóa
Tài liệu tham khảo
Tol, 2009, Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer, N. Engl. J. Med., 360, 563, 10.1056/NEJMoa0808268
Fojo, 2009, How much is life worth: cetuximab, non-small cell lung cancer, and the $440billion question, J. Natl. Cancer Inst., 101, 1044, 10.1093/jnci/djp177
Wood, 2007, The genomic landscapes of human breast and colorectal cancers, Science, 318, 1108, 10.1126/science.1145720
Sjöblom, 2006, The consensus coding sequences of human breast and colorectal cancers, Science, 314, 268, 10.1126/science.1133427
Torchilin, 2011, Tumor delivery of macromolecular drugs based on the EPR effect, Adv. Drug Deliv. Rev., 63, 131, 10.1016/j.addr.2010.03.011
Matsumura, 1986, A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS, Cancer Res., 46, 6387
Maeda, 2001, The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting, 189
Maeda, 2001, SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy, Adv. Drug Deliv. Rev., 46, 169, 10.1016/S0169-409X(00)00134-4
Fang, 2003, Factors and mechanism of “EPR” effect and the enhanced antitumor effects of macromolecular drugs including SMANCS, Adv. Exp. Med. Biol., 519, 29, 10.1007/0-306-47932-X_2
Seki, 2009, Tumor targeted macromolecular drug delivery based on the enhanced permeability and retention effect in solid tumor, 93
Maeda, 2009, Polymeric drugs and nanomedicines for efficient tumor targeted drug delivery based on EPR-effect, Eur. J. Pharm. Biopharm., 71, 409, 10.1016/j.ejpb.2008.11.010
Maeda, 2006, The EPR effect and polymeric drugs: a paradigm shift for cancer chemotherapy in the 21st century, Adv. Polym. Sci., 193, 103, 10.1007/12_026
Iyer, 2006, Exploiting the enhanced permeability and retention effect for tumor targeting, Drug Discov. Today, 11, 812, 10.1016/j.drudis.2006.07.005
Vicent, 2009, Polymer therapeutics: clinical applications and challenges for development, Adv. Drug Deliv. Rev., 61, 1117, 10.1016/j.addr.2009.08.001
Duncan, 2003, The dawning era of polymer therapeutics, Nat. Rev. Drug Discov., 2, 347, 10.1038/nrd1088
Matsumura, 2009, Preclinical and clinical studies of anticancer agent-incorporating polymer micelles, Cancer Sci., 100, 572, 10.1111/j.1349-7006.2009.01103.x
Maki, 1985, Image enhancement in computerized tomography for sensitive diagnosis of liver cancer and semiquantitation of tumor selective drug targeting with oily contrast medium, Cancer, 56, 751, 10.1002/1097-0142(19850815)56:4<751::AID-CNCR2820560409>3.0.CO;2-Y
Nagamitsu, 2009, Elevating blood pressure as a strategy to increase tumor-targeted delivery of macromolecular drug SMANCS: cases of advanced solid tumors, Jpn. J. Oncol., 39, 756, 10.1093/jjco/hyp074
Maeda, 1979, A lipophilic derivative of neocarzinostatin. A polymer conjugation of an antitumor protein antibiotic, Int. J. Pept. Protein Res., 14, 81, 10.1111/j.1399-3011.1979.tb01730.x
Maeda, 1984, Tailor-making of protein drugs by polymer conjugation for tumor targeting: a brief review on smancs, J. Protein Chem., 3, 181, 10.1007/BF01040499
Maeda, 1983, Cancer selective macromolecular therapeutics: tailoring of an antitumor protein drug, 353
Fang, 2002, Tumor-targeted delivery of polyethylene glycol-conjugated d-amino acid oxidase for antitumor therapy via enzymatic generation of hydrogen peroxide, Cancer Res., 62, 3138
Fang, 2003, In vivo antitumor activity of pegylated zinc protoporphyrin: targeted inhibition of heme oxygenase in solid tumor, Cancer Res., 63, 3567
Iyer, 2007, High-loading nanosized micelles of copoly(styrene-maleic acid)-zinc protoporphyrin for targeted delivery of a potent heme oxygenase inhibitor, Biomaterials, 28, 1871, 10.1016/j.biomaterials.2006.11.051
Greish, 2005, Copoly(styrene-maleic acid)-pirarubicin micelles: high tumor-targeting efficiency with little toxicity, Bioconjug. Chem., 16, 230, 10.1021/bc040297g
Greish, 2004, SMA-doxorubicin, a new polymeric micellar drug for effective targeting to solid tumours, J. Control. Release, 97, 219, 10.1016/j.jconrel.2004.03.027
Maeda, 1989, Tumoritropic and lymphotropic principles of macromolecular drugs, Crit. Rev. Ther. Drug Carrier Syst., 6, 193
Greish, 2003, Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumor targeting, Clin. Pharmacokinet., 42, 1089, 10.2165/00003088-200342130-00002
Konno, 1984, Selective targeting of anti-cancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium, Cancer, 54, 2367, 10.1002/1097-0142(19841201)54:11<2367::AID-CNCR2820541111>3.0.CO;2-F
Maeda, 2001, Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS, J. Control. Release, 74, 47, 10.1016/S0168-3659(01)00309-1
Noguchi, 1998, Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues, Jpn. J. Cancer Res., 89, 307, 10.1111/j.1349-7006.1998.tb00563.x
Seymour, 1995, Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier, Eur. J. Cancer, 31A, 766, 10.1016/0959-8049(94)00514-6
Zhao, 2005, Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium, Proc. Natl. Acad. Sci. U. S. A., 102, 755, 10.1073/pnas.0408422102
Zhao, 2006, Targeted therapy with a Salmonella typhimurium leucine–arginine auxotroph cures orthotopic human breast tumors in nude mice, Cancer Res., 66, 7647, 10.1158/0008-5472.CAN-06-0716
Hoffman, 2009, Tumor-targeting amino acid auxotrophic Salmonella typhimurium, Amino Acids, 37, 509, 10.1007/s00726-009-0261-8
Sawa, 2000, Tumor-targeting chemotherapy by a xanthine oxidase-polymer conjugate that generates oxygen-free radicals in tumor tissue, Cancer Res., 60, 666
Campbell, 2002, Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors, Cancer Res., 62, 6831
Nakamura, 1998, Uptake and gene expression of naked plasmid DNA in cultured brain microvessel endothelial cells, Biochem. Biophys. Res. Commun., 245, 235, 10.1006/bbrc.1998.8334
Li, 2008, Pharmacokinetics and biodistribution of nanoparticles, Mol. Pharm., 5, 496, 10.1021/mp800049w
Keyler, 2006, Pharmacokinetics and toxicity of high-dose human α1-acid glycoprotein infusion in the rat, J. Pharm. Sci., 76, 101, 10.1002/jps.2600760203
Gregoriadis, 2008, Liposome research in drug delivery: the early days, J. Drug Target., 16, 520, 10.1080/10611860802228350
Allen, 1991, Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo, Biochim. Biophys. Acta, 1066, 29, 10.1016/0005-2736(91)90246-5
Immordino, 2006, Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential, Int. J. Nanomed., 1, 297
Owens, 2006, Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles, Int. J. Pharm., 307, 93, 10.1016/j.ijpharm.2005.10.010
Li, 2006, Surface-modified LPD nanoparticles for tumor targeting, Ann. N.Y. Acad. Sci., 1082, 1, 10.1196/annals.1348.001
Ishida, 2006, Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes, J. Control. Release, 112, 15, 10.1016/j.jconrel.2006.01.005
Ishida, 2008, Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes, Int. J. Pharm., 354, 56, 10.1016/j.ijpharm.2007.11.005
Hatakeyama, 2007, Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid, Gene Ther., 14, 68, 10.1038/sj.gt.3302843
Masuda, 2009, Envelope-type lipid nanoparticles incorporating a short PEG-lipid conjugate for improved control of intracellular trafficking and transgene transcription, Biomaterials, 27, 4806, 10.1016/j.biomaterials.2009.05.036
Nakamura, 2010, Intracellular Uptake of Water Soluble ZnPP Micelles (SMA-ZnPP and PEG-ZnPP) and the Unique Release Mechanism of the Drug from Their Micelles
Daniels, 2006, The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells, Clin. Immunol., 121, 159, 10.1016/j.clim.2006.06.006
Sundaram, 2009, Surface-functionalized nanoparticles for targeted gene delivery across nasal respiratory epithelium, FASEB J., 23, 3752, 10.1096/fj.09-129825
Yang, 2009, Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2, Mol. Pharm., 6, 221, 10.1021/mp800149s
Taketani, 2007, Carboxylesterase in the liver and small intestine of experimental animals and human, Life Sci., 81, 924, 10.1016/j.lfs.2007.07.026
Folkman, 1971, Tumor angiogenesis in cancer, therapeutic implications, N. Engl. J. Med., 285, 1182, 10.1056/NEJM197111182852108
Folkman, 1995, Angiogenesis in cancer, vascular, rheumatoid and other diseases, Nat. Med., 1, 27, 10.1038/nm0195-27
Folkman, 1990, What is the evidence that tumors are angiogenesis dependent?, J. Natl. Cancer Inst., 82, 4, 10.1093/jnci/82.1.4
Daruwalla, 2009, Styrene maleic acid-pirarubicin disrupts tumor microcirculation and enhances the permeability of colorectal liver metastases, J. Vasc. Res., 46, 218, 10.1159/000165380
Maeda, 2003, Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications, Int. Immunopharmacol., 3, 319, 10.1016/S1567-5769(02)00271-0
Hori, 1991, Fluctuations in tumor blood flow under normotension and the effect of angiotensin II-induced hypertension, Jpn. J. Cancer Res., 82, 1309, 10.1111/j.1349-7006.1991.tb01797.x
Suzuki, 1981, A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with angiotensin II, J. Natl. Cancer Inst., 67, 663
Skinner, 1990, Microvascular architecture of experimental colon tumors in the rat, Cancer Res., 50, 2411
Suzuki, 1987, Medial regression and its functional significance in tumor-supplying host arteries, Cancer, 59, 444, 10.1002/1097-0142(19870201)59:3<444::AID-CNCR2820590316>3.0.CO;2-5
Greish, 2006, Enhanced permeability and retention (EPR) effect and tumor-selective delivery of anticancer drugs, 37
Hori, 2000, Tumor-selective blood flow decrease induced by an angiotensin converting enzyme inhibitor, temocapril hydrochloride, Jpn. J. Cancer Res., 91, 261, 10.1111/j.1349-7006.2000.tb00940.x
Iwai, 1984, Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X-ray image, Cancer Res., 44, 2115
Konno, 1992, Targeting chemotherapy for hepatoma: arterial administration of anticancer drugs dissolved in Lipiodol, Eur. J. Cancer, 28, 403, 10.1016/S0959-8049(05)80063-2
Maeda, 1980, Lymphotropic accumulation of an antitumor antibiotic protein, neocarzinostatin, Eur. J. Cancer, 16, 723, 10.1016/0014-2964(80)90215-7
Maeda, 1979, Antimetastatic and antitumor activity of a derivative of neocarzinostatin: an organic solvent- and water-soluble polymer-conjugated protein, Gann, 70, 601
Yamasaki, 1987, Reduction of hepatic metastases in rabbits by administration of an oily anticancer agent into the portal vein, Cancer Res., 47, 852
Ohtsuka, 1987, Anticancer effects of arterial administration of the anticancer agent SMANCS with lipiodol on metastatic lymph nodes, Cancer, 59, 1560, 10.1002/1097-0142(19870501)59:9<1560::AID-CNCR2820590905>3.0.CO;2-J
Maeda, 1988, Purification and identification of [hydroxyprolyl3]bradykinin in ascitic fluid from a patient with gastric cancer, J. Biol. Chem., 263, 16,051, 10.1016/S0021-9258(18)37555-0
Matsumura, 1988, Involvement of the kinin-generating cascade in enhanced vascular permeability in tumor tissue, Jpn. J. Cancer Res., 79, 1327, 10.1111/j.1349-7006.1988.tb01563.x
Matsumura, 1991, Kinin-generating cascade in advanced cancer patients and in vitro study, Jpn. J. Cancer Res., 82, 732, 10.1111/j.1349-7006.1991.tb01910.x
Wu, 1998, Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger, Cancer Res., 58, 159
Doi, 1996, Excessive production of nitric oxide in rat solid tumor and its implication in rapid tumor growth, Cancer, 77, 1598, 10.1002/(SICI)1097-0142(19960415)77:8<1598::AID-CNCR27>3.0.CO;2-U
Maeda, 1994, Enhanced vascular permeability in solid tumor is mediated by nitric oxide and inhibited by both nitric oxide scavenger and nitric oxide synthase inhibitor, Jpn. J. Cancer Res., 85, 331, 10.1111/j.1349-7006.1994.tb02362.x
Wu, 2001, Enhanced vascular permeability in solid tumor involving peroxynitrite and matrix metalloproteinases, Jpn. J. Cancer Res., 92, 439, 10.1111/j.1349-7006.2001.tb01114.x
Reichman, 1986, Effect of steroids and nonsteroid anti-inflammatory agents on vascular permeability in a rat glioma model, J. Neurosurg., 65, 233, 10.3171/jns.1986.65.2.0233
Senger, 1983, Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid, Science, 219, 983, 10.1126/science.6823562
Ferrara, 1989, Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells, Biochem. Biophys. Res. Commun., 161, 851, 10.1016/0006-291X(89)92678-8
Rosenthal, 1990, Conditioned medium from mouse sarcoma 180 cells contains vascular endothelial growth factor, Growth Factors, 4, 53, 10.3109/08977199009011010
Leung, 1989, Vascular endothelial growth factor is a secreted angiogenic mitogen, Science, 246, 1306, 10.1126/science.2479986
Keck, 1989, Vascular permeability factor, an endothelial cell mitogen related to PDGF, Science, 246, 1309, 10.1126/science.2479987
Kano, 2009, Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-β receptor inhibitor on extravasation of nanoparticles from neovasculature, Cancer Sci., 100, 173, 10.1111/j.1349-7006.2008.01003.x
Del Rosso, 2008, The plasminogen activation system in inflammation, Front. Biosci., 13, 4667, 10.2741/3032
Maeda, 1999, Kallikrein–kinin in infection and cancer, Immunopharmacology, 43, 115, 10.1016/S0162-3109(99)00104-6
Wu, 2002, Identification of bradykinin receptors in clinical cancer specimens and murine tumor tissues, Int. J. Cancer, 98, 29, 10.1002/ijc.10142
Bhoola, 1992, Bioregulation of kinins: kallikreins, kininogens, and kininases, Pharmacol. Rev., 44, 1
Bhoola, 2001, Kallikrein and kinin receptor expression in inflammation and cancer, Biol. Chem., 382, 77, 10.1515/BC.2001.013
Kou, 2002, Dephosphorylation of endothelial nitric-oxide synthase by vascular endothelial growth factor. Implications for the vascular responses to cyclosporine A, J. Biol. Chem., 277, 29,669, 10.1074/jbc.M204519200
Doi, 1999, Induction of haem oxygenase-1 by nitric oxide and ischaemia in experimental solid tumours and implications for tumour growth, Br. J. Cancer, 80, 1945, 10.1038/sj.bjc.6690624
Kisley, 2002, Genetic ablation of inducible nitric oxide synthase decreases mouse lung tumorigenesis, Cancer Res., 62, 6850
Beckman, 1990, Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide, Proc. Natl. Acad. Sci. U. S. A., 87, 1620, 10.1073/pnas.87.4.1620
Beckman, 1996, Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly, Am. J. Physiol., 271, C1424, 10.1152/ajpcell.1996.271.5.C1424
Akaike, 2000, Nitric oxide and virus infection, Immunology, 101, 300, 10.1046/j.1365-2567.2000.00142.x
Akaike, 2000, Pathophysiological effects of high-output production of nitric oxide, 733
Akaike, 1998, Free radicals in viral pathogenesis: molecular mechanisms involving superoxide and NO, Proc. Soc. Exp. Biol. Med., 217, 64, 10.3181/00379727-217-44206
Maeda, 1999, Free radical generation from heterocyclic amines by cytochrome b5 reductase in the presence of NADH, Cancer Lett., 143, 117, 10.1016/S0304-3835(99)00139-1
Sawa, 2003, Superoxide generation mediated by 8-nitroguanosine, a highly redox-active nucleic acid derivative, Biochem. Biophys. Res. Commun., 311, 300, 10.1016/j.bbrc.2003.10.003
Okamoto, 1997, Activation of human neutrophil procollagenase by nitrogen dioxide and peroxynitrite: a novel mechanism for procollagenase activation involving nitric oxide, Arch. Biochem. Biophys., 342, 261, 10.1006/abbi.1997.0127
Kuwahara, 2009, Generation of drug-resistant mutants of Helicobacter pylori in the presence of peroxynitrite, a derivative of nitric oxide, at pathophysiological concentration, Microbiol. Immunol., 53, 1, 10.1111/j.1348-0421.2008.00089.x
Massova, 1998, Matrix metalloproteinases: structures, evolution, and diversification, FASEB J., 12, 1075, 10.1096/fasebj.12.12.1075
Himelstein, 1994, Metalloproteinases in tumor progression: the contribution of MMP-9, Invasion Metastasis, 14, 246
Chambers, 1997, Changing views of the role of matrix metalloproteinases in metastasis, J. Natl. Cancer Inst., 89, 1260, 10.1093/jnci/89.17.1260
Yoneda, 1998, Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice, J. Natl. Cancer Inst., 90, 447, 10.1093/jnci/90.6.447
Sawa, 2007, Protein S-guanylation by the biological signal 8-nitroguanosine 3′, 5′-cyclic monophosphate, Nat. Chem. Biol., 3, 727, 10.1038/nchembio.2007.33
Chand, 1977, Bradykinin relaxes contracted airways through prostaglandin production, J. Pharm. Pharmacol., 29, 387, 10.1111/j.2042-7158.1977.tb11349.x
Furuta, 2000, Effects of inflammatory cytokines on prostaglandin E2 production from human amnion cells cultured in serum-free condition, Gynecol. Obstet. Invest., 49, 93, 10.1159/000010222
Tanaka, 2003, Modulation of tumor-selective vascular blood flow and extravasation by the stable prostaglandin I2 analogue beraprost sodium, J. Drug Target., 11, 45, 10.1080/1061186031000086072
Grothey, 2009, Targeting angiogenesis: progress with anti-VEGF treatment with large molecules, Nat. Rev. Clin. Oncol., 6, 507, 10.1038/nrclinonc.2009.110
Dvorak, 1995, Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis, Am. J. Pathol., 146, 1029
Murohara, 1998, Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin, Circulation, 97, 99, 10.1161/01.CIR.97.1.99
Papapetropoulos, 1997, Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells, J. Clin. Invest., 100, 3131, 10.1172/JCI119868
Li, 1993, Augmentation of tumor delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure, Br. J. Cancer, 67, 975, 10.1038/bjc.1993.179
Jordan, 2000, Changes in tumor oxygenation/perfusion induced by the NO donor, isosorbide dinitrate, in comparison with carbogen: monitoring by EPR and MRI, Int. J. Radiat. Oncol. Biol. Phys., 48, 565, 10.1016/S0360-3016(00)00694-5
Mitchell, 1993, Hypoxic mammalian cell radiosensitization by nitric oxide, Cancer Res., 53, 5845
Fukuto, 2000, The chemical properties of nitric oxide and related nitrogen oxides, 23
Feelisch, 1987, Correlation between nitric oxide formation during degradation of organic nitrates and activation of guanylate cyclase, Eur. J. Pharmacol., 139, 19, 10.1016/0014-2999(87)90493-6
Seki, 2009, Enhanced delivery of macromolecular antitumor drugs to tumors by nitroglycerin application, Cancer Sci., 100, 2426, 10.1111/j.1349-7006.2009.01323.x
Kojima, 1999, Fluorescent indicators for imaging nitric oxide production, Angew. Chem. Int. Ed. Engl., 38, 3209, 10.1002/(SICI)1521-3773(19991102)38:21<3209::AID-ANIE3209>3.0.CO;2-6
Pasut, 2009, Polymer–drug conjugates for combination anticancer therapy: investigating the mechanism of action, J. Med. Chem., 52, 6499, 10.1021/jm900804m
Santucci, 2006, Nitric oxide modulates proapoptotic and antiapoptotic properties of chemotherapy agents: the case of NO-pegylated epirubicin, FASEB J., 20, 765, 10.1096/fj.05-4452fje
Santucci, 2007, Cardiac safety and antitumoral activity of a new nitric oxide derivative of pegylated epirubicin in mice, Anticancer Drugs, 18, 1081, 10.1097/CAD.0b013e3281db8322
Yasuda, 2006, Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small cell lung cancer, J. Clin. Oncol., 24, 688, 10.1200/JCO.2005.04.0436
Yasuda, 2006, Nitroglycerin treatment may increase response to docetaxel and carboplatin regimen via inhibitions of hypoxia-inducible factor-1 pathway and P-glycoprotein in patients with lung adenocarcinoma, Clin. Cancer Res., 12, 6748, 10.1158/1078-0432.CCR-06-1124
Yasuda, 2009, Therapeutic applications of nitric oxide for malignant tumor in animal models and human studies
Siemens, 2009, Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer, Urology, 74, 878, 10.1016/j.urology.2009.03.004
Akaike, 1993, Antagonistic action of imidazolineoxyl N-oxides against endothelium-derived relaxing factor/.NO through a radical reaction, Biochemistry, 32, 827, 10.1021/bi00054a013